Povorcitinib + Placebo

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Hidradenitis Suppurativa (HS)

Conditions

Hidradenitis Suppurativa (HS)

Trial Timeline

Dec 19, 2022 → Dec 23, 2025

NCT ID

NCT05620823

About Povorcitinib + Placebo

Povorcitinib + Placebo is a phase 3 stage product being developed by Incyte for Hidradenitis Suppurativa (HS). The current trial status is completed. This product is registered under clinical trial identifier NCT05620823. Target conditions include Hidradenitis Suppurativa (HS).

What happened to similar drugs?

1 of 20 similar drugs in Hidradenitis Suppurativa (HS) were approved

Approved (1) Terminated (0) Active (19)

✅Placebo + AdalimumabAbbVieApproved

🔄SonelokimabMoonLake ImmunotherapeuticsPhase 3

🔄Sonelokimab + PlaceboMoonLake ImmunotherapeuticsPhase 3

🔄Lutikizumab + PlaceboAbbViePhase 3

🔄Upadacitinib + PlaceboAbbViePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06516952	Phase 3	Recruiting	Oct 10, 2024	May 3, 2027	Prurigo Nodularis
NCT06516965	Phase 3	Recruiting	Oct 10, 2024	May 3, 2027	Prurigo Nodularis
NCT06113445	Phase 3	Active	Nov 29, 2023	Feb 24, 2027	NonSegmental Vitiligo
NCT06113471	Phase 3	Active	Nov 27, 2023	Mar 16, 2027	NonSegmental Vitiligo
NCT05936567	Phase 2	Completed	Jul 31, 2023	Oct 9, 2025	Urticaria
NCT05620836	Phase 3	Completed	Feb 22, 2023	Nov 21, 2025	Hidradenitis Suppurativa (HS)
NCT05620823	Phase 3	Completed	Dec 19, 2022	Dec 23, 2025	Hidradenitis Suppurativa (HS)

Competing Products

20 competing products in Hidradenitis Suppurativa (HS)

See all competitors

Product	Company	Stage	Hype Score
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab	MoonLake Immunotherapeutics	Phase 3	41
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab + Placebo	MoonLake Immunotherapeutics	Phase 3	38
Sonelokimab (M1095) + Adalimumab	MoonLake Immunotherapeutics	Phase 2	29
Eltrekibart + Placebo	Eli Lilly	Phase 2	39
Placebo + LY3041658	Eli Lilly	Phase 2	35
Placebo + Adalimumab	AbbVie	Approved	43
Lutikizumab + Placebo	AbbVie	Phase 3	47
Adalimumab	AbbVie	Pre-clinical	26
Upadacitinib + Placebo	AbbVie	Phase 3	47
adalimumab + placebo	AbbVie	Phase 3	40
Lutikizumab	AbbVie	Phase 2	42
adalimumab	AbbVie	Phase 3	40
Lutikizumab + Placebo	AbbVie	Phase 2	39
Risankizumab + Placebo for risankizumab	AbbVie	Phase 2	35
adalimumab	AbbVie	Phase 3	40
adalimumab + placebo	AbbVie	Phase 3	40
Upadacitinib + Placebo	AbbVie	Phase 2	35
MEDI8968 + Saline	AstraZeneca	Phase 2	27